Adiponectin as a biomarker in liver cirrhosis—A systematic review and meta‐analysis
European Journal of Clinical Investigation · 2025
DOI: 10.1111/eci.14328 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Abdulrahman Ismaiel und 6 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Adiponectin, Liver Cirrhosis, Biomarkers, Liver Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Adiponectin, a key adipokine, shows promise as a non‐invasive biomarker for liver cirrhosis by reflecting inflammation and metabolic changes, but conflicting findings highlight the need for a systematic review and meta‐analysis to clarify its role. Our study aimed to evaluate adiponectin levels across various stages of liver cirrhosis, compare them with other chronic liver diseases (CLD) and hepatocellular carcinoma (HCC), and assess its potential as a diagnostic and prognostic biomarker.
Methods
Our systematic search was conducted on September 2023 using PubMed, EMBASE and Scopus, searching for observational studies evaluating serum and plasma adiponectin levels in liver cirrhosis. Inclusion and exclusion criteria were applied, and study quality was assessed using the Newcastle‐Ottawa Scale. To evaluate the overall effect size, we utilized a random‐effects model along with a mean difference (MD) analysis. The principal summary outcome was the MD in adiponectin levels.
Results
We included 16 articles involving 2617 subjects in our qualitative and quantitative synthesis. We found significantly higher adiponectin levels in liver cirrhosis patients (8.181 [95% CI 3.676, 12.686]), especially in Child‐Pugh B individuals (13.294 [95% CI 4.955, 21.634]), compared to controls. Child‐Pugh A patients did not show significant differences compared to controls. In addition, adiponectin levels were significantly elevated in primary biliary cholangitis (PBC) patients compared to controls (8.669 [95% CI .291, 17.047]), as well as in liver cirrhosis compared to other CLD patients (4.805 [95% CI 1.247, 8.363]), including non‐alcoholic fatty liver disease (NAFLD) (8.532 [95% CI 3.422, 13.641]), but not viral hepatitis. No significant MD was observed between liver cirrhosis and HCC patients.
Conclusion
Adiponectin levels are significantly elevated in liver cirrhosis, especially in advanced stages, potentially serving as a biomarker for advanced cirrhosis. Adiponectin also differentiates cirrhosis from other CLD, including NAFLD. However, its role in distinguishing cirrhosis from viral hepatitis and HCC is limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 2nd Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- Department of General Surgery, Altnagelvin Hospital, Londonderry, UK.
- Department of Medical Informatics and Biostatistics, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
ORCID-Profile: Abdulrahman Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Dan L Dumitrascu
Zitieren
APA
Ismaiel, A., Ciornolutchii, V., Herrera, T. E., Ismaiel, M., Leucuta, D. C., Popa, S. L., & Dumitrascu, D. L. (2025). Adiponectin as a biomarker in liver cirrhosis—A systematic review and meta‐analysis. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14328
Vancouver
Ismaiel A, Ciornolutchii V, Herrera TE, Ismaiel M, Leucuta DC, Popa SL, et al. Adiponectin as a biomarker in liver cirrhosis—A systematic review and meta‐analysis. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.14328
BibTeX
@article{Ismaiel2025,
author = {Ismaiel, Abdulrahman and Ciornolutchii, Vera and Herrera, Thelva Esposito and Ismaiel, Mohamed and Leucuta, Daniel-Corneliu and Popa, Stefan-Lucian and Dumitrascu, Dan L},
title = {Adiponectin as a biomarker in liver cirrhosis—A systematic review and meta‐analysis},
journal = {European Journal of Clinical Investigation},
year = {2025},
doi = {10.1111/eci.14328}
}
EUVIMED